Illuccix targets prostate-specific membrane antigens. The authorization allows Czech physicians to use it before it has been granted full European clearance, according to the firm. The approval is the first in Europe for the product, according to Telix.

Illuccix is under review by the U.S. Food and Drug Administration, Australia's Therapeutic Goods Administration, the European Union, and Canada, Telix said.